<DOC>
	<DOCNO>NCT02282423</DOCNO>
	<brief_summary>The goal study understand insulin resistant individual respond differently exercise compare insulin sensitive individual skeletal muscle gene expression level .</brief_summary>
	<brief_title>PGC-1 &amp; Muscle Mitochondrial Dysfunction Diabetes</brief_title>
	<detailed_description>The goal study understand insulin resistant individual respond differently exercise compare insulin sensitive individual skeletal muscle gene expression level . The study four aim include test MZF1 , NFKB1 , RELA , SP1/KLF EGRI expression response outside normal range insulin resistant individual insulin resistance change cell biosynthesis process/ post translational modification . It also aim define response MiRNAs healthy insulin resistant individual determine treatment Gemfibrozil inhibit transcription process .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<criteria>Aims13 1 . Age 3059 2 . BMI : Lean , BMI le equal 25 ; Obese , BMI 3040 ; type 2 diabetic , BMI 3040 . 3 . Subjects must able communicate meaningfully investigator must legally competent provide write informed consent . 4 . Subjects may either sex age describe protocol . Female subject must nonlactating eligible negative pregnancy test throughout study period . 5 . Subjects must range age describe specific protocol . 6 . Subjects must follow laboratory value : Hematocrit ≥ 35 vol % Serum creatinine ≤ 1.6 mg/dl AST ( SGOT ) &lt; 2 time upper limit normal ALT ( SGPT ) &lt; 2 time upper limit normal Alkaline phosphatase &lt; 2 time upper limit normal Triglycerides &lt; 150 mg/dl ( except Aim 4 ) . Aim 4 1 . Age 3059 2 . BMI : Lean , BMI le equal 25 ; Obese , BMI 3040 . 3 . Patients may normal impaired glucose tolerance . 4 . Subjects must able communicate meaningfully investigator must legally competent provide write informed consent . 5 . Subjects may either sex age describe protocol . Female subject must nonlactating eligible negative pregnancy test throughout study period . 6 . Subjects must follow laboratory value : Hematocrit ≥ 35 vol % Serum creatinine ≤ 1.6 mg/dl AST ( SGOT ) &lt; 2 time upper limit normal ALT ( SGPT ) &lt; 2 time upper limit normal Alkaline phosphatase &lt; 2 time upper limit normal Triglycerides &gt; 300 mg/dl nondiabetics , &gt; 250 mg/dl impair glucose tolerance . 1 . Subjects must receive follow medication : thiazide furosemide diuretic , betablockers , chronic medication know adverse effect glucose tolerance level unless patient stable dose agent past three month entry study . Subjects may take stable dose estrogens hormonal replacement therapy , subject agent prior three month . Subjects take systemic glucocorticoid exclude . Patients type 2 diabetes exclude take metformin thiazolidinediones , may take sulfonylureas medication know work effect insulin secretion . 2 . Subjects receive Gemfibrozil must also receive statin . 3 . Subjects history clinically significant heart disease ( New York Heart Classification great grade II ; nonspecific STT wave change EKG ) , peripheral vascular disease ( history claudication ) , pulmonary disease ( dyspnea exertion one flight le ; abnormal breath sound auscultation ) study . 4 . Recent systemic pulmonary embolus , untreated highrisk proliferative retinopathy , recent retinal hemorrhage , uncontrolled hypertension , systolic BP &gt; 180 , diastolic BP &gt; 105 , autonomic neuropathy , rest heart rate &gt; 100 , electrolyte abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>